Drugs / V116
Trials 11 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04665050 | Feb → Apr 2021 | pneumococcal infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04168190 | Dec 2019 → Jul 2021 | streptococcal pneumonia | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 39 trials | ||||||
| Phase 3 | NCT06177912 | Jan 2024 → Feb 2025 | pneumococcal infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT05696080 | Feb 2023 → Feb 2024 | pneumococcal infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT05633992 | Jan → May 2023 | pneumococcal infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT05569954 | Nov 2022 → Oct 2023 | pneumococcal infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT05526716 | Sep 2022 → Jun 2023 | streptococcal pneumonia | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT05464420 | Aug 2022 → May 2023 | pneumococcal infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT05425732 | Jul 2022 → May 2023 | pneumococcal infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT05393037 | Jul 2022 → Jul 2023 | pneumococcal infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT05420961 | Jul 2022 → May 2023 | streptococcal pneumonia | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | V116 | “Background: V116 is a 21-valent pneumococcal conjugate vaccine (PCV) designed for adults.” PMID 40333240 ↗ Mar 2025 |
| Modality | Vaccine | “Pneumococcal 21-valent conjugate vaccine with 2 μg of each of the following pneumococcal polysaccharides (PnPs) antigen” NCT04665050 ↗ |
| Route | Intramuscular | “a single intramuscular (IM) dose of V116 on Day 1” NCT05393037 ↗ |